Cohort study on testicular cancer follow-up strategies
Official title: Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
Run by Cantonal Hospital of St. Gallen · NCT02229916 · Data updated 2026-11-12
This study looks at different ways to check for any return of testicular cancer in patients who are in complete remission to see which methods work best for their follow-up care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 6900 (estimated) |
| Sponsor | Cantonal Hospital of St. Gallen Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Sankt Gallen) |
| Status | Recruiting |
| Started | December 2013 |
| Main results expected | December 2028 |
| Study ends | December 2033 |
| Registry record updated | January 13, 2026 |
| Trial ID | NCT02229916 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include young men with histologically proven seminomas or non-seminomas who have recently completed treatment and are in complete remission.
✕Probably not a fit
Patients with co-existing malignancies or those unable to comply with follow-up schedules may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the effectiveness of various diagnostic tests and follow-up strategies for patients with testicular cancer who have achieved complete remission. It focuses on the early detection of relapses using methods such as radiographs, CT scans, and serum tumor markers, while also assessing the patterns of care and long-term outcomes for these patients. The study seeks to standardize follow-up procedures to improve patient care and minimize unnecessary interventions. By collecting data on treatment sequelae and patient characteristics, the study aims to enhance understanding of the disease's impact on survivors.
Why it matters
Potential benefit: If successful, this study could lead to improved follow-up protocols that enhance early relapse detection and reduce unnecessary treatments for testicular cancer survivors.
How similar studies have gone: Other studies have shown success in improving follow-up strategies for testicular cancer, making this approach both relevant and necessary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written informed consent. * Histologically proven seminomas or non-seminoma. * Seminoma: complete remission (CR) or lymph nodes (LN) \< 3cm or PET negative partial remission (PR) or non-seminoma: CR. * Completion of treatment within the last 6 months. * Patient able and willing to attend for regular surveillance. Exclusion Criteria: * Co-existent malignancy within 5 years. * Inability for any reason to comply with the trial investigations or follow-up schedules.
Where it's running
-
Kantonsspital St.Gallen; Onkologie/Haematologie
Sankt Gallen, Switzerland Recruiting
Study contacts
- Principal investigator: Christian Rothermundt, Dr. med. — Cantonal Hospital of St. Gallen
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding lymphedema after urologic surgery
This study looks at how often and how badly lymphedema affects people after they have surgery for urologic cancer that involves removing lymph nodes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.